Sharp Therapeutics Corp. Reports First Quarter 2025 Results
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 22, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces the release of its condensed interim consolidated financial statements for the three months ended March 31, 2025, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our Q1 financial results show...
2025-05-22 5:45 PM EDT
Sharp Therapeutics Corp. Nominates Clinical Candidate for Gaucher's Disease
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces that it has nominated a small molecule compound from its GBA program for clinical development in Gaucher's disease. Sharp has launched its clinical development program for Gaucher's disease by nominating a compound from the SEL-148,721 series of GBA1-restoring small molecules to enter IND-enabling studies. The company...
2025-05-13 5:05 PM EDT
STX PARTNERS LLP and Newlin Investment Co. Exercise Warrants of Sharp Therapeutics Corp.
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing small molecule therapies to treat hereditary disorders, is pleased to announce that STX PARTNERS LLP ("STX") and Newlin Investment Company ("NIC") have each exercised their respective common share purchase warrants of the Company (the "Warrants") for aggregate gross proceeds to the Company of US$2.5M.The Warrants were issued pursuant to the Common Stock Purchase Agreement entered...
2025-04-21 5:05 PM EDT
Sharp Therapeutics Corp. Completes Share Consolidation
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical stage biotechnology company specializing in small molecule drugs to treat genetic diseases, is pleased to announce the successful completion of its previously announced consolidation of its common shares (the "Common Shares") on the basis of one (1) post-consolidation Common Share for every ten (10) pre-consolidation Common Shares, with any resulting fractional shares rounded up to the nearest whole number (the...
2025-01-27 8:24 AM EST
Sharp Therapeutics Corp. Announces Share Consolidation
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 16, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical stage biotechnology company specializing in small molecule drugs to treat genetic diseases, announces that its board of directors has approved a consolidation (the "Consolidation") of the Company's issued and outstanding common shares (the "Common Shares") on the basis of ten (10) pre-consolidation shares for one (1) post-consolidated share. The purpose of the Consolidation is to facilitate the...
2025-01-16 8:53 AM EST
Sharp Therapeutics Corp. Announces Completion of Qualifying Transaction
Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Sharp Therapeutics Corp. (TSXV: EVP.P) ("Sharp Therapeutics"), formerly EVP Capital Inc. ("EVP Capital"), an Ontario corporation is pleased to announce the successful completion of its qualifying transaction by way of a reverse takeover of Sharp Edge Labs, Inc. ("Sharp Edge") under the policies of the TSX Venture Exchange (the "TSXV"). Pursuant to a statutory plan of arrangement under the Business Corporations Act (Ontario) (the "OBCA"), EVP Capital acquired all the issued and outstanding...
2024-12-12 1:36 PM EST
EVP Capital Announces Delivery of Management Information Circular in Connection with Annual General and Special Meeting and Encourages Shareholders to Access Meeting Materials Electronically
Toronto, Ontario--(Newsfile Corp. - November 25, 2024) - EVP Capital Inc., an Ontario corporation (TSXV: EVP.P) ("EVP Capital") has delivered and is in the process of continuing to effect delivery of the management information circular (the "Circular") and related materials for the annual general and special meeting (the "Meeting") of holders of common shares ("EVP Shares") of EVP Capital ("EVP Shareholders") to be held December 6, 2024. At the Meeting, EVP Shareholders will be asked, among other matters further described...
2024-11-25 8:30 AM EST
EVP Capital Files its Proxy Circular for Upcoming Shareholder Meeting to Approve its Plan of Arrangement Transaction with Sharp Edge
Toronto, Ontario--(Newsfile Corp. - November 1, 2024) - EVP Capital Inc., an Ontario corporation (TSXV: EVP.P) ("EVP Capital"), is pleased to announced that, in accordance with National Instrument 51-102 - Continuous Disclosure Obligations, it has filed its management information circular (the "Circular") and related proxy materials in respect of its annual and special meeting of shareholders of EVP Capital to be held on December 6, 2024 at 12:00 p.m. (Toronto time) (the "Meeting") to approve its previously announced statutory...
2024-11-01 6:32 PM EDT
EVP Capital Receives Conditional Approval from TSX Venture Exchange on Qualifying Transaction with Sharp Edge and Court Approval to Call Shareholder Meeting
Toronto, Ontario--(Newsfile Corp. - October 21, 2024) - EVP Capital Inc., an Ontario corporation (TSXV: EVP.P) ("EVP Capital"), is pleased to announced that is has received conditional approval from the TSX Venture Exchange ("TSXV") for its previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) whereby SEL AcquisitionCo Inc. ("Merger Sub"), a Delaware incorporated wholly-owned subsidiary of EVP Capital, will acquire all of the issued and outstanding shares of Sharp Edge Labs, Inc., an...
2024-10-21 8:30 AM EDT
EVP Capital Announces Receipt of Interim Order in Respect of Proposed Arrangement with Sharp Edge and Provides Details of Shareholder Meeting
Toronto, Ontario--(Newsfile Corp. - July 30, 2024) - EVP Capital Inc., an Ontario corporation (TSXV: EVP.P) ("EVP Capital"), is pleased to announce that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted an interim order (the "Interim Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "OBCA"), pursuant to which, subject to the satisfaction or waiver of all applicable conditions precedent, SEL AcquisitionCo Inc. ("Merger...
2024-07-30 4:01 PM EDT
EVP Capital Announces Agreement for Proposed Qualifying Transaction
Toronto, Ontario--(Newsfile Corp. - July 2, 2024) - EVP Capital Inc., an Ontario corporation (TSXV: EVP.P) ("EVP Capital"), is pleased to announce that it has entered into a definitive arrangement agreement and plan of merger dated June 28, 2024 (the "Arrangement Agreement") by and among EVP Capital, Sharp Edge Labs, Inc., a Delaware corporation ("Sharp Edge") and SEL AcquisitionCo Inc. ("Merger Sub"), a Delaware incorporated wholly-owned subsidiary of EVP Capital. The Arrangement Agreement contemplates that EVP Capital will acquire all...
2024-07-02 8:30 AM EDT